ProCE Banner Activity

AVANOVA2 Extended Follow-up: Niraparib Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

Slideset Download
Conference Coverage
In this updated analysis, niraparib plus bevacizumab prolonged PFS and time to subsequent therapies over niraparib alone in patients with platinum-sensitive recurrent ovarian cancer.

Released: June 08, 2020

Expiration: June 07, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono